Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies

Zeuschner, Philip; Linxweiler, Johannes; Junker, Kerstin

doi:10.1080/14737159.2019.1665998

Cited by 42 publications

(35 citation statements)

References 191 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study reveals that the majority of transcripts that are upregulated in cancer patient plasma are in fact non-coding transcripts. Indeed, some studies [41,42] have reported non-coding RNAs as liquid biopsy-based biomarkers in cancer. Very few coding transcripts were identified, most probably because of endogenous cellular degradation of these transcripts following translation by the CNOT complex [43].…”

Section: Discussionmentioning

confidence: 99%

Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer

Metzenmacher

Váraljai

Hegedűs

et al. 2020

Cancers

View full text Add to dashboard Cite

Early detection of cancer holds high promise for reducing cancer-related mortality. Detection of circulating tumor-specific nucleic acids holds promise, but sensitivity and specificity issues remain with current technology. We studied cell-free RNA (cfRNA) in patients with non-small cell lung cancer (NSCLC; n = 56 stage IV, n = 39 stages I-III), pancreatic cancer (PDAC, n = 20 stage III), malignant melanoma (MM, n = 12 stage III-IV), urothelial bladder cancer (UBC, n = 22 stage II and IV), and 65 healthy controls by means of next generation sequencing (NGS) and real-time droplet digital PCR (RT-ddPCR). We identified 192 overlapping upregulated transcripts in NSCLC and PDAC by NGS, more than 90% of which were noncoding. Previously reported transcripts (e.g., HOTAIRM1) were identified. Plasma cfRNA transcript levels of POU6F2-AS2 discriminated NSCLC from healthy donors (AUC = 0.82 and 0.76 for stages IV and I–III, respectively) and significantly associated (p = 0.017) with the established tumor marker Cyfra 21-1. cfRNA yield and POU6F2-AS transcript abundance discriminated PDAC patients from healthy donors (AUC = 1.0). POU6F2-AS2 transcript was significantly higher in MM (p = 0.044). In summary, our findings support further validation of cfRNA detection by RT-ddPCR as a biomarker for early detection of solid cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer

Metzenmacher

Váraljai

Hegedűs

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…In this sense, most of the studies investigated cfRNA profiles but there are suggestions to start focusing on circulating EVs and their cargos [15]. However, the results are still inconclusive and, in general, the available studies did not investigate the potentiality of these biomarkers in distinguishing among subtypes of BC [16].…”

Section: Introductionmentioning

confidence: 99%

Small Non-Coding RNA Profiling in Plasma Extracellular Vesicles of Bladder Cancer Patients by Next-Generation Sequencing: Expression Levels of miR-126-3p and piR-5936 Increase with Higher Histologic Grades

Sabo

Birolo

Naccarati

et al. 2020

Cancers

View full text Add to dashboard Cite

Bladder cancer (BC) is the tenth most frequent cancer worldwide. Due to the need for recurrent cystoscopies and the lack of non-invasive biomarkers, BC is associated with a high management burden. In this respect, small non-coding RNAs (sncRNAs) have been investigated in urine as possible biomarkers for BC, but in plasma their potential has not yet been defined. The expression levels of sncRNAs contained in plasma extracellular vesicles (EVs) from 47 men with BC and 46 healthy controls were assessed by next-generation sequencing. The sncRNA profiles were compared with urinary profiles from the same subjects. miR-4508 resulted downregulated in plasma EVs of muscle-invasive BC patients, compared to controls (adj-p = 0.04). In World Health Organization (WHO) grade 3 (G3) BC, miR-126-3p was upregulated both in plasma EVs and urine, when compared to controls (for both, adj-p < 0.05). Interestingly, two sncRNAs were associated with the risk class: miR-4508 with a downward trend going from controls to high risk BC, and piR-hsa-5936 with an upward trend (adj-p = 0.04 and adj-p = 0.05, respectively). Additionally, BC cases with low expression of miR-185-5p and miR-106a-5p or high expression of miR-10b-5p showed shorter survival (adj-p = 0.0013, adj-p = 0.039 and adj-p = 0.047, respectively). SncRNAs from plasma EVs could be diagnostic biomarkers for BC, especially in advanced grade.

show abstract

“…12 lncRNAs can be used as 1) chromatin modified scaffolds, 2) bait-induced transcriptional inhibitors, 3) RNA processing guides, or 4) signals of gene activation. 13 Recent evidence suggested that lncRNAs play a key role in many biological processes, such as inflammation, cell growth, cell differentiation, and tumorigenesis. 14,15 lncRNAs have a regulatory function in human diseases, especially cancer.…”

Section: Introductionmentioning

confidence: 99%

“…16,17 lncRNA not only was detected in cancer tissues, but also was in various body fluids, including, urine, blood and saliva. 13 Exosomes have been proven to be a bridge for the exchange of important information between cells, carrying nucleic acids, proteins, and lipids to recipient cells. 18 Interestingly, exosomes also carry a wide range of lncRNAs.…”

Section: Introductionmentioning

confidence: 99%

The Biological Roles of Exosomal Long Non-Coding RNAs in Cancers

Da¹,

Jiang²,

Xie

et al. 2021

OTT

View full text Add to dashboard Cite

Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies

Cited by 42 publications

References 191 publications

Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer

Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer

Small Non-Coding RNA Profiling in Plasma Extracellular Vesicles of Bladder Cancer Patients by Next-Generation Sequencing: Expression Levels of miR-126-3p and piR-5936 Increase with Higher Histologic Grades

The Biological Roles of Exosomal Long Non-Coding RNAs in Cancers

Contact Info

Product

Resources

About